References
- Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, Phase 3 non-inferiority trial. Lancet doi:10.1016/S0140-6736(12)61763-2 (2013) (Epub ahead of print).
- Cheson BD, Wendtner CM, Pieper A et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin. Lymphoma Myeloma Leuk. 10(1), 21–27 (2010).
Websites
- Rummel MJ, Niederle N, Maschmeyer G et al. Subanalysis of the StiL NHL 1-2003 study: achievement of complete response with bendamustine–rituximab (B–R) and CHOP-R in the first-line treatment of indolent and mantle cell lymphomas results in superior survival compared to partial response. https://ash.confex.com/ash/2012/webprogram/Paper48063.html
- Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab (B–R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95807
- Flinn IW, van der Jagt RH, Kahl BS et al. An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin’s lymphoma (NHL) or mantle cell lymphoma (MCL): the BRIGHT study. https://ash.confex.com/ash/2012/webprogram/Paper51442.html